Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of Candida albicans and Aspergillus fumigatus infections

International Journal of Antimicrobial Agents

Volumn 12, Issue 3, 1999, Pages 221-228

  Niwano, Yoshimi ^a   Kuzuhara, Naoki ^a   Goto, Yuri ^a   Munechika, Yukimi ^a   Kodama, Hiroki ^a   Kanai, Kazuo ^a   Yoshida, Masanori ^a   Miyazaki, Tsuneo ^a   Yamaguchi, Hideyo ^b  

^a NIHON NOHYAKU CO LTD   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

Aspergillus fumigatus; Candida albicans; Experimental infection; Imidazole antimycotic; NND 502

Indexed keywords

[4 (2,4 DICHLOROPHENYL) 1,3 DITHIOLAN 2 YLIDENE](1 IMIDAZOLYL)ACETONITRILE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG POTENCY; INTRAVENOUS DRUG ADMINISTRATION; LUNG ASPERGILLOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; IMIDAZOLES; LUNG DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032800374     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00076-X     Document Type: Article

References (45)

1. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal-infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-57.
2. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
3. Hay RJ. Overview of the treatment of disseminated fungal infections. J Antimicrob Chemother 1991;28 (Suppl. B):17-25.
4. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
5. Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone-marrow transplant-attributable mortality and risk-factors. Cancer 1992;69:2653-62.
6. Pfaller MA. Epidemiology and control of fungal infections. Clin Infect Dis 1994;19(Suppl. 1):S8-S13.
7. Kauffman CA, Carver PL. Antifungal agents in the 1990s. Current status and future developments. Drugs 1997;53:539-49.
8. Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992;44:9-35.
9. Sternberg S. The emerging fungal threat. Science 1994;266:1632-4.
10. Maddux MS, Barriere SL. A review of complications of amphotericin B therapy: recommendations for prevention and management. Drug Intell Clin Pharm 1980;14:177-81.
11. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Safety 1990;5:94-108.
12. Warda J, Barriere SL. Amphotericin B nephrotoxicity. Drug Intell Clin Pharm 1985;24:275-80.
13. Armstrong D, Schmitt HJ. Older drugs. In: Ryley JF, editor. Chemotherapy of Fungal Diseases. Berlin: Springer-Verlag, 1990.
14. Walsh TJ, Pizzo PA. Treatment of systemic fungal infections: recent progress and current problems. Eur J Clin Microbiol Infect Dis 1988;7:460-75.
15. Cutsem JV, Gerven FV, Ven MAV, Borgers M, Janssen PAJ. Itraconazole, a new triazole that is orally active in aspergillosis. Antimicrob Agents Chemother 1984;26:527-34.
16. Cutsem JV, Gerven FV, Janssen PAJ. Oral and parenteral therapy with saperconazole (R66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother 1989;33:2063-8.
17. Fierer J, Kirkland T, Finley F. Comparison of fluconazole and SDZ89-485 for therapy of experimental murine coccidioidomycosis. Antimicrob Agents Chemother 1990;34:13-6.
18. Ichise K, Tanio T, Saji I, Okuda T. Activity of SM-4470, new imidazole derivative, against experimental fungal infection. Antimicrob Agents Chemother 1986;30:366-9.
19. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997;41:13-6.
20. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1504-7.
21. Plempel M. Antimycotic activity of BAYn7133 in animal experiments. Antimicrob Agents Chemother 1984;13:447-63.
22. Richardson K, Brammer KW, Marriott MS, Troke PF. Activity of UK-49,858, a bis-triazole derivative, against experimental infection with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother 1985;27:832-5.
23. Ryley JF, McGregor S, Wilson RG. Activity of ICI195,739 - a novel, orally active bistriazole-in rodent models of fungal and protozoal infections. Ann NY Acad Sci 1988;544:310-28.
24. Tanio T, Ichise K, Nakajima T, Okuda T. In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. Antimicrob Agents Chemother 1990;34:980-4.
25. Yamada H, Tsuda T, Watanabe T, Ohashi M, Murakami K, Mochizuki H. In vitro and in vivo antifungal activities of D0870, a new triazole agent. Antimicrob Agents Chemother 1993;37:2412-7.
26. Troke PF, Andrews RJ, Brammer KW, Marriott MS, Richardson K. Efficacy of UK-49,858 (fluconazole) against Candida albicans experimental infections in mice. Antimicrob Agents Chemother 1985;28:815-8.
27. Yozwiak ML, Galgiani JN. Itraconazole treatment of experimental systemic candidiasis in male rats. J Med Vet Mycol 1987;25:125-6.
28. Troke PF, Andrews RJ, Marriott MS, Richardson K. Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice. J Antimicrob Chemother 1987;19:663-70.
29. Baily GG, Perry FM, Denning DW, Mandal BK. Fluconazole-resistant candidosis in an HIV cohort. AIDS 1994;8:787-92.
30. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995;35:103-14.
31. Law D, Moore CB, Wardle HM, Ganguli LA, Keaney MGL, Denning DW. High prevalence of antifungal resistance in Candida in AIDS. J Antimicrob Chemother 1994;34:659-68.
32. Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother 1988;32:1310-3.
33. Niwano Y, Kuzuhara N, Kodama H, Yoshida M, Miyazaki T, Yamaguchi H. In vitro and in vivo antidermatophyte activities of NND-502, a novel optically active imidazole antimycotic agent. Antimicrob Agents Chemother 1998;42:967-70.
34. Heeres J, Backx LJJ, Cutsem JV. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem 1984;27:894-900.
35. Kodama H, Niwano Y, Kanai K, Yoshida M. Japanese patent (Jpn Kokai Tokkyo Koho) H9-100279, 1997.
36. Narayanaswami S, Richardson K. Eur Patent EP96569, 1983.
37. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 1997.
38. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal azoles. Antimicrob Agents Chemother 1992;36:477-80.
39. Hostetler JS, Hanson LH, Stevens DA. Effect of hydroxypropyl-beta-cyclodextrin on efficacy of oral itraconazole in disseminated murine cryptococcosis. J Antimicrob Chemother 1993;32:459-63.
40. Schmitt HJ, Bernard EM, Häuser M, Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988;32:1676-9.
41. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother 1985;28:648-53.
42. Cicogna CE, White MH, Bernard EM, et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41:259-61.
43. Kurtz MB, Bernard EM, Edwards FF, et al. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995;39:1784-9.
44. Miyazaki HM, Kohno S, Miyazaki Y, et al. Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis. Antimicrob Agents Chemother 1993;37:2762-5.
45. Niki Y, Bernard EM, Edwards FF, Schmitt HJ, Yu B, Armstrong D. Model of recurrent pulmonary aspergillosis in rats. J Clin Microb 1991;29:1317-32.